Alzheimer’s drug from Biogen wins US approval →
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy. THE FINANCIAL TIMES
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy. THE FINANCIAL TIMES